AU2001287977A1 - Controlled release formulations for oral administration - Google Patents

Controlled release formulations for oral administration

Info

Publication number
AU2001287977A1
AU2001287977A1 AU2001287977A AU8797701A AU2001287977A1 AU 2001287977 A1 AU2001287977 A1 AU 2001287977A1 AU 2001287977 A AU2001287977 A AU 2001287977A AU 8797701 A AU8797701 A AU 8797701A AU 2001287977 A1 AU2001287977 A1 AU 2001287977A1
Authority
AU
Australia
Prior art keywords
oral administration
controlled release
release formulations
formulations
controlled
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001287977A
Other languages
English (en)
Inventor
Gour Mukherji
Rajeev S. Raghuvanshi
Ashok Rampal
Narayanan Badri Vishwanathan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ranbaxy Laboratories Ltd
Original Assignee
Ranbaxy Laboratories Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from IN856DE2000 external-priority patent/IN192864B/en
Application filed by Ranbaxy Laboratories Ltd filed Critical Ranbaxy Laboratories Ltd
Publication of AU2001287977A1 publication Critical patent/AU2001287977A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5386—1,4-Oxazines, e.g. morpholine spiro-condensed or forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU2001287977A 2000-09-22 2001-09-22 Controlled release formulations for oral administration Abandoned AU2001287977A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
IN856DE2000 IN192864B (fr) 2000-09-22 2000-09-22
IN856/DEL/2000 2000-09-22
IN881DE2001 2001-08-24
IN881/DEL/2001 2001-08-24
PCT/IB2001/001743 WO2002024203A2 (fr) 2000-09-22 2001-09-22 Formulation à administrer oralement à libération contrôlée

Publications (1)

Publication Number Publication Date
AU2001287977A1 true AU2001287977A1 (en) 2002-04-02

Family

ID=26324883

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001287977A Abandoned AU2001287977A1 (en) 2000-09-22 2001-09-22 Controlled release formulations for oral administration

Country Status (9)

Country Link
US (1) US20020119192A1 (fr)
EP (1) EP1322313A2 (fr)
KR (1) KR20030048410A (fr)
CN (1) CN1471398A (fr)
AP (1) AP2003002763A0 (fr)
AU (1) AU2001287977A1 (fr)
BR (1) BR0114100A (fr)
MX (1) MXPA03002569A (fr)
WO (1) WO2002024203A2 (fr)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR0313207A (pt) * 2002-08-02 2005-06-28 Ranbaxy Lab Ltd Comprimidos de fosinopril de sódio estável ao armazenamento, processo para sua preparação e método para tratar a hipertensão
US20040202717A1 (en) 2003-04-08 2004-10-14 Mehta Atul M. Abuse-resistant oral dosage forms and method of use thereof
WO2004096182A1 (fr) * 2003-04-30 2004-11-11 Ranbaxy Laboratories Limited Comprimes matriciels a liberation prolongee de carvedilol
US8627828B2 (en) 2003-11-07 2014-01-14 U.S. Smokeless Tobacco Company Llc Tobacco compositions
CN102669810B (zh) 2003-11-07 2014-11-05 美国无烟烟草有限责任公司 烟草组合物
HUE031058T2 (en) 2004-03-29 2017-06-28 Servier Lab A method of producing a solid pharmaceutical composition
US20050220873A1 (en) * 2004-04-02 2005-10-06 Chien-Hsuan Han Pharmaceutical dosage forms having immediate and controlled release properties that contain a GABAB receptor agonist
US20050260263A1 (en) * 2004-05-18 2005-11-24 Panion & Bf Biotech Inc. Sustained release formulation for sparingly soluble main drugs
US20060045911A1 (en) * 2004-08-27 2006-03-02 Sun Pharmaceutical Industries Ltd. Stable pharmaceutical formulations
US20070092565A1 (en) * 2005-10-25 2007-04-26 Pharmascience Inc. Gastric retention drug delivery system
CA2691956A1 (fr) * 2007-06-25 2008-12-31 Pharmathen S.A. Formulation pharmaceutique amelioree contenant un inhibiteur de la hmg-coa reductase et son procede de preparation
US20120027855A1 (en) * 2007-07-06 2012-02-02 Lupin Limited Pharmaceutical compositions for gastrointestinal drug delivery
JP2012500221A (ja) 2008-08-15 2012-01-05 ディポメド，インコーポレイティド Ｃｎｓ障害の処理及び予防のための胃保持性医薬組成物
BRPI0914080A2 (pt) * 2008-10-08 2015-10-27 Bioplus Life Sciences Pvt Ltda "sistema de liberação de dosagem controlada, método de administração e processo de preparação do mesmo"
WO2010106555A2 (fr) * 2009-03-17 2010-09-23 Shantilal, Doshi, Bimalkumar Polymère d'éther de cellulose prégranulé directement compressible et procédé pour préparer celui-ci
WO2011101866A2 (fr) 2010-02-17 2011-08-25 Sun Pharma Advanced Research Company Ltd., Méthode de traitement d'une affection sensible à une thérapie par baclofène
JP2015525800A (ja) 2012-08-07 2015-09-07 トップジェニックス, インコーポレーテッドTopgenix, Inc. 関心のある化合物（目的化合物）を発現する形質転換細菌を含む局所用組成物
BR112017013598A2 (pt) * 2014-12-23 2018-03-06 Fmc Corp composições de revestimento de película entérico, método de revestimento, e formas revestidas
US11324774B2 (en) * 2018-01-05 2022-05-10 Augusta University Research Institute, Inc. Compositions of oral alkaline salts and metabolic acid inducers and uses thereof
CN110840866A (zh) * 2018-08-20 2020-02-28 成都新睿泰康科技有限公司 一种细辛脑药物组合物及其在防治神经退行性疾病方面的应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3681754D1 (de) * 1985-04-27 1991-11-07 Nitto Denko Corp Klebepflaster und arzneimittel fuer die mundhoehle.
US5686094A (en) * 1991-04-01 1997-11-11 Theratech, Inc. Controlled release formulations for the treatment of xerostomia
CA2107678A1 (fr) * 1991-04-08 1992-10-09 Kouichi Nakamichi Capsule
WO2000035418A2 (fr) * 1998-12-18 2000-06-22 Bayer Corporation Systeme d'administration de medicament a croquer
US6248363B1 (en) * 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions

Also Published As

Publication number Publication date
WO2002024203A3 (fr) 2002-11-07
CN1471398A (zh) 2004-01-28
AP2003002763A0 (en) 2003-03-31
BR0114100A (pt) 2003-10-21
EP1322313A2 (fr) 2003-07-02
US20020119192A1 (en) 2002-08-29
KR20030048410A (ko) 2003-06-19
WO2002024203A2 (fr) 2002-03-28
MXPA03002569A (es) 2003-10-14

Similar Documents

Publication Publication Date Title
AU2002258563A1 (en) Pharmaceutical formulations for sustained release
AU6089200A (en) Rapid immediate release oral dosage form
AU3977099A (en) Controlled release oral dosage form
AU2276801A (en) Extended release oral dosage composition
AU2002229140A1 (en) Controlled release pharmaceutical composition
AU2277101A (en) Stable extended release oral dosage composition
AU2001287977A1 (en) Controlled release formulations for oral administration
GB0025208D0 (en) Delayed release pharmaceutical formulations
AU2001248769A1 (en) Time-release coated solid compositions for oral administration
AU2002239397A1 (en) Drug formulation having improved oral tolerability
AU2003213151A1 (en) Controlled release solid dosage carbamazepine formulations
AU2001280908A1 (en) Rotavirus vaccine formulations
AU2001284444A1 (en) Preparations for oral administration
AU2002214324A1 (en) Medicinal compositions
EP1207852A4 (fr) Dosage oral a liberation regulee destine a l'administration orale
HUP0301177A3 (en) Ion-strength independent sustained release pharmaceutical formulation
AU2001272314A1 (en) Oral formulations for localized colonic release and the method of preparation thereof
AU2001256201A1 (en) Device for administering implants
AU6715600A (en) Pharmaceutical formulations
AU2001290239A1 (en) Medicinal composition
AU2564399A (en) Isoflavanoid formulations for oral administration
AU2001248336A1 (en) Controlled release oral solid forms containing mesalazine as active agent
AU2001248772A1 (en) Sustained release drug compositions
IL148908A0 (en) Oral controlled release formulations
AU1732401A (en) Medicinal compositions for oral use